ZNTL
—
—
Loading…
—
—
MASTER
—
—
ESEN VERDICT
Analyzing…
Horizon6–12M
Confidence—
Data coverage—
SNAPSHOT
Ticker
ZNTL
Company
Zentalis Pharmaceuticals Inc
Sector / Industry
Biotechnology / Biotechnology
Market Cap
$316.6M
Current Price
$3.65 −12.0%
52-Week Range
$1.21 – $6.95
52-Week Return
+204.3%
Beta
1.95 (High Volatility)
EARNINGS MOMENTUM
⚠ Data Constraint: Quarterly EPS actuals, estimates, and revenue history not available in current dataset. Assessment based on trailing metrics.
| Metric | Value | Status |
|---|---|---|
| EPS (TTM) | −$1.91 | Negative |
| EPS Growth YoY | No Data | Not Disclosed |
| Revenue Growth YoY | No Data | Not Disclosed |
| Forward EPS Growth | No Data | Not Disclosed |
| Guidance Trend | Not Available | Limited Visibility |
Earnings Momentum Score: 2/10 — Company is pre-revenue or early-stage clinical with negative EPS. No earnings history or guidance visible. Significant execution risk ahead.
PROFITABILITY & QUALITY
⚠ Data Constraint: Income statement and cash flow data not currently available. Assessment constrained to observable metrics.
| Metric | Value | Assessment |
|---|---|---|
| Gross Margin | No Data | Not Available |
| Operating Margin | No Data | Not Available |
| Net Margin | No Data | Not Available |
| ROE / ROIC | No Data | Not Available |
| Free Cash Flow (TTM) | No Data | Not Available |
| FCF Trend | No Data | Not Available |
Quality Score: 1/10 — Early-stage biotech with no profitability, negative earnings, and no disclosed financial statements. Quality data insufficient. High burn-rate risk implied by negative EPS and small market cap.
BALANCE SHEET HEALTH
⚠ Data Constraint: Balance sheet detail (cash, debt, equity) not available in current dataset. Risk assessment constrained.
| Metric | Value | Status |
|---|---|---|
| Cash & Equivalents | No Data | Not Disclosed |
| Total Debt | No Data | Not Disclosed |
| Net Debt / EBITDA | No Data | Not Applicable |
| Current Ratio | No Data | Not Available |
| Interest Coverage | No Data | Not Available |
| Share Dilution Trend | No Data | Not Visible |
Balance Sheet Risk: HIGH — Pre-revenue/early-stage biotech carries inherent funding and cash runway risk. Negative EPS and $316.6M market cap suggest limited resources for extended R&D cycles. Financing dilution likely. Detailed balance sheet critical but unavailable.
VALUATION ANALYSIS
⚠ Data Constraint: Forward P/E, PEG, and sector comparables not available. Traditional valuation metrics not applicable to pre-revenue biotech.
| Metric | Value | Context |
|---|---|---|
| Trailing P/E | N/A | Negative Earnings |
| Forward P/E | No Data | Not Available |
| PEG Ratio | No Data | Not Applicable |
| Price/Sales | No Data | No Revenue Disclosed |
| Price/FCF | No Data | No FCF Data |
| EV/EBITDA | No Data | Not Applicable |
| Sector Median Comparison | Not Available | Limited Visibility |
Valuation Status: SPECULATIVE — Traditional metrics inapplicable. For pre-revenue biotech, valuation depends entirely on pipeline value, clinical trial success probability, and time to commercialization. Current $316.6M market cap reflects extreme risk discount. 52-week swing ($1.21–$6.95) indicates sentiment volatility. Fundamentals-based valuation impossible; candidate for event-driven or venture-backed thesis only.
ANALYST TARGETS & SENTIMENT
⚠ Data Constraint: Consensus rating, target prices, and analyst coverage not currently available.
| Metric | Value | Status |
|---|---|---|
| Consensus Rating | No Data | Not Available |
| Target Price (Mean) | No Data | Not Available |
| Target High / Low | No Data | Not Available |
| Implied Upside / Downside | No Data | Not Available |
| Analyst Dispersion | No Data | Not Available |
| Analyst Count | No Data | Not Available |
Wall Street Sentiment: INSUFFICIENT COVERAGE — No analyst target or consensus rating visible. Early-stage biotech companies often have sparse coverage. Unable to assess institutional research consensus. Recommend checking Benzinga, Yahoo Finance, or company investor relations for recent research notes.
INSTITUTIONAL & RISK CHECK
⚠ Data Constraint: Institutional ownership, insider activity, and short interest not currently available.
| Risk Factor | Indicator | Severity |
|---|---|---|
| Institutional Ownership Trend | No Data | Not Available |
| Insider Trading Activity | No Data | Not Available |
| Short Interest % | No Data | Not Available |
| Clinical Trial Risk | Implied High | CRITICAL |
| Cash Runway Risk | Implied High | CRITICAL |
| Regulatory / Approval Risk | Implied High | CRITICAL |
| Share Dilution Risk | Implied High | HIGH |
| Volatility (Beta) | 1.95 | HIGH |
Risk Level: VERY HIGH — Pre-revenue biotech with negative EPS, high beta (1.95), and no disclosed cash position. Primary risks: (1) clinical trial failure, (2) cash runway / financing dilution, (3) regulatory rejection, (4) no clear path to profitability disclosed. Speculative profile. Suitable only for risk-tolerant portfolios with deep biotech expertise. Detailed pipeline, capital structure, and burn-rate review essential before investment.
FINAL ESEN VERDICT
20
Fundamental Score (0–100)
Conviction Level: VERY LOW — Speculative Only
Time Horizon Grid
Short (1–3M)
SELL
Medium (6–12M)
AVOID
Long (2Y+)
HIGH RISK
Final Summary
- Pre-Revenue / Early-Stage: Negative EPS (−$1.91), no revenue disclosed, no profitability pathway visible. Entirely development-stage.
- Capital Constraints: $316.6M market cap insufficient for extended Phase II/III trials. Cash runway and financing dilution risk extreme.
- Valuation Speculative: Traditional metrics inapplicable. 52-week range ($1.21–$6.95) reflects extreme sentiment volatility. Price driven by pipeline perception, not fundamentals.
- High Volatility & Risk: Beta 1.95 indicates double market risk. Clinical failure, cash burn, regulatory rejection, or shareholder dilution could trigger sharp declines. Candidate for venture/biotech specialists only.
- Data Gaps Critical: No financial statements, analyst coverage, or guidance available. Investment thesis requires direct access to pipeline data, clinical trial status, and capital structure. Professional biotech due diligence mandatory.
Recommendation: NOT SUITABLE FOR FUNDAMENTAL INVESTORS. Approve only for biotech-specialist portfolios with high risk tolerance. Requires deep pipeline and capital structure analysis before commitment. Current fundamental score reflects severe data constraints and inherent pre-revenue risk profile. Re-assess upon revenue milestone or clinical approval announcement.
AI STOCK INSIGHT
ZNTL Stock Analysis & Forecast
Is ZNTL a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
ZNTL Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, ZNTL shows balanced risk-reward characteristics.
Should You Buy ZNTL Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in ZNTL.